Study: NCT02612051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.